Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04387461 · ClinicalTrials.gov registry record · Phase 2
Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin
A Phase 2 study, sponsored by CG Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT04387461: Completed Phase 2 study, sponsored by CG Oncology.
NCT04387461 is a Phase 2 study that has completed, run by CG Oncology. The registered enrollment target is 35 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04387461, a Phase 2 study, has completed, sponsored by CG Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
To evaluate the activity of intravesical administration of CG0070 and intravenous administration of Pembrolizumab in patients with tissue pathology-confirmed non-muscle invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease with carcinoma in situ (CIS) with or without Ta/T1 papillary disease.
Primary Outcome
Percentage of patients with a complete response as defined by FDA guidance document dated February 2018 for NMIBC.
Interventions
- BIOLOGICAL Pembrolizumab Injection
- BIOLOGICAL CG0070
- OTHER n-dodecyl-B-D-maltoside
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2020-12-08 |
| Est. Completion | 2024-05-28 |
| Phase | Phase 2 |
What the finished NCT04387461 record still lists
NCT04387461 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab Injection is the first listed.
NCT04387461 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04387461 about?
NCT04387461 is a clinical study titled "Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin". To evaluate the activity of intravesical administration of CG0070 and intravenous administration of Pembrolizumab in patients with tissue pathology-confirmed non-muscle invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease with carcinoma in situ (CIS) with or w...
What is the current status of trial NCT04387461?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2020-12-08. Estimated completion is 2024-05-28.
What interventions are being tested in trial NCT04387461?
The interventions under investigation include: Pembrolizumab Injection (BIOLOGICAL), CG0070 (BIOLOGICAL), n-dodecyl-B-D-maltoside (OTHER).
Who is sponsoring clinical trial NCT04387461?
This trial is sponsored by CG Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04387461's enrollment target sits among peer trials
35 1524th of 2000 higher than 462 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI